The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

Lactobacillus salivarius BP121 prevents cisplatin‑induced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and p‑cresol sulfate via alleviating dysbiosis

(2020) Tae‑Hee Lee et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study

(2020) Frank B. Cortazar et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

M2 macrophages predict worse long-term outcomes in human acute tubular necrosis

(2020) Myung-Gyu Kim et al.   Scientific Reports

Treatment of immune checkpoint inhibitor-induced inflammatory arthritis

(2020) Susanna Jeurling et al.   CURRENT OPINION IN RHEUMATOLOGY

Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients

(2020) Lisa Derosa et al.   EUROPEAN UROLOGY

Molecular Mechanisms of Premature Aging in Hemodialysis: The Complex Interplay between Innate and Adaptive Immune Dysfunction

(2020) Vincenzo Losappio et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

(2020) Chaomin Wu et al.   JAMA Internal Medicine

Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage

(2020) Rossana Franzin et al.   Frontiers in Immunology

Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers

(2019) R. C. Liu et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

(2019) Omar Mamlouk et al.   Journal for ImmunoTherapy of Cancer

Pre-existing malignancies in renal transplant candidates—time to reconsider waiting times

(2019) Bruno Watschinger et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Modulating the microbiome to improve therapeutic response in cancer

(2019) Jennifer L McQuade et al.   LANCET ONCOLOGY

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy

(2019) Tian Tian et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma

(2019) Giuseppe Lucarelli et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?

(2019) Hung-Chih Lai et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

M2 macrophages in kidney disease: biology, therapies, and perspectives

(2019) Titi Chen et al.   KIDNEY INTERNATIONAL

Complement component C5a induces aberrant epigenetic modifications in renal tubular epithelial cells accelerating senescence by Wnt4/βcatenin signaling after ischemia/reperfusion injury

(2019) Giuseppe Castellano et al.   Aging-US

Use of Cell Cycle Arrest Biomarkers in Conjunction With Classical Markers of Acute Kidney Injury

(2019) Michael Joannidis et al.   CRITICAL CARE MEDICINE

Targeting mTOR for cancer therapy

(2019) Hui Hua et al.   Journal of Hematology & Oncology

Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy

(2019) Xiaojie Yu et al.   mAbs

Urine macrophages reflect kidney macrophage content during acute tubular interstitial and glomerular injury

(2019) Ping-ping Sun et al.   CLINICAL IMMUNOLOGY

Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?

(2019) Mark A. Perazella et al.   KIDNEY INTERNATIONAL

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Poor Outcomes with the Use of Checkpoint Inhibitors in Kidney Transplant Recipients.

(2019) Karthik Venkatachalam et al.   TRANSPLANTATION

The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors

(2019) Harish Seethapathy et al.   Clinical Journal of the American Society of Nephrology

Lactate up-regulates the expression of PD-L1 in kidney and causes immunosuppression in septic Acute Renal Injury

(2019) Jingjing Xu et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

(2019) Shuang Qin et al.   Molecular Cancer

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation

(2019) Khashayar Esfahani et al.   Nature Communications

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

(2019) Satya Das et al.   Journal for ImmunoTherapy of Cancer

The Role of Biomarkers in Acute Kidney Injury

(2019) Nattachai Srisawat et al.   CRITICAL CARE CLINICS

Th17 cells contribute to pulmonary fibrosis and inflammation during chronic kidney disease progression after acute ischemia

(2018) Purvi Mehrotra et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Improving Clinical Prediction Rules In Acute Kidney Injury With The Use of Biomarkers of Cell Cycle Arrest: A Pilot Study.

(2018) Luke E Hodgson et al.   BIOMARKERS

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results

(2018) Jacques Dantal et al.   JOURNAL OF CLINICAL ONCOLOGY

Gut microbiome modulates efficacy of immune checkpoint inhibitors

(2018) Ming Yi et al.   Journal of Hematology & Oncology

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

(2018) Florentia Dimitriou et al.   JOURNAL OF IMMUNOTHERAPY

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future

(2018) Mark A. Perazella et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade

(2018) Sara Valpione et al.   Journal of Translational Medicine

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

(2018) Fabio Conforti et al.   LANCET ONCOLOGY

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

(2018) Jennifer L McQuade et al.   LANCET ONCOLOGY

The use of cell cycle arrest biomarkers in the early detection of acute kidney injury. Is this the new renal troponin?

(2018) Luis M. Ortega et al.   NEFROLOGIA

Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis

(2018) Sandhya Manohar et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report

(2018) Ryo Koda et al.   BMC Nephrology

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

(2018) Taku Fujimura et al.   Oncotarget

Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan

(2018) Shu-Yung Lin et al.   Journal of Cancer

Reversing the immune ageing clock: lifestyle modifications and pharmacological interventions

(2018) Niharika A. Duggal   BIOGERONTOLOGY

Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma

(2018) B. Rousseau et al.   INTERNATIONAL JOURNAL OF CANCER

Senescence markers - predictive for response to checkpoint inhibitors?

(2018) Alvaro Moreira et al.   INTERNATIONAL JOURNAL OF CANCER

The Human Gut Microbiome – A Potential Controller of Wellness and Disease

(2018) Zhi Y. Kho et al.   Frontiers in Microbiology

Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

(2018) Xinyu Yan et al.   Frontiers in Pharmacology

Risk of lung cancer in lung transplant recipients in the United States

(2018) Matthew Triplette et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis

(2018) Ping Li et al.   OncoTargets and Therapy

A possible interaction between periostin and CD163+ skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid

(2017) Taku Fujimura et al.   EXPERIMENTAL DERMATOLOGY

Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment

(2017) Tadashi Tabei et al.   INTERNATIONAL JOURNAL OF UROLOGY

Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity

(2017) Ryota Tanaka et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma

(2017) Robin A. Daanen et al.   JOURNAL OF IMMUNOTHERAPY

Manipulating the gut microbiome to decrease uremic toxins

(2017) Rabi Yacoub et al.   KIDNEY INTERNATIONAL

Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS–based metabolomics approach

(2017) Eikan Mishima et al.   KIDNEY INTERNATIONAL

Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup

(2017) Lakhmir S. Chawla et al.   Nature Reviews Nephrology

Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients

(2017) Edward B. Garon   NEW ENGLAND JOURNAL OF MEDICINE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab

(2017) Richard Barnett et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection

(2017) Stanley C. Jordan et al.   TRANSPLANTATION

Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient

(2017) Clément Deltombe et al.   TRANSPLANTATION

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors

(2017) Adam Diehl et al.   Oncotarget

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

(2017) Guillermo De Velasco et al.   Cancer Immunology Research

Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice

(2017) Anjelique F. Schulfer et al.   Nature Microbiology

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

(2017) Julia Escandon et al.   Journal for ImmunoTherapy of Cancer

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

(2016) Anushree C. Shirali et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Lung–Kidney Cross-Talk in the Critically Ill Patient

(2016) Faeq Husain-Syed et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy

(2016) C. L. Boils et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection

(2016) T. Alhamad et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

(2016) S Diem et al.   BRITISH JOURNAL OF CANCER

Acute interstitial nephritis related to immune checkpoint inhibitors

(2016) Julie Belliere et al.   BRITISH JOURNAL OF CANCER

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients

(2016) Ryutaro Ishitsuka et al.   Clinical and Experimental Nephrology

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

(2016) Benjamin Weide et al.   CLINICAL CANCER RESEARCH

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

(2016) A. Martens et al.   CLINICAL CANCER RESEARCH

Drug-induced nephropathies

(2016) Paisit Paueksakon et al.   HISTOPATHOLOGY

Systemic over-release of interleukin-17 in acute kidney injury after septic shock: Clinical and experimental evidence

(2016) Panagiota Maravitsa et al.   IMMUNOLOGY LETTERS

Depletion of Gut Microbiota Protects against Renal Ischemia-Reperfusion Injury

(2016) Diba Emal et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

mTOR inhibitors effects on regulatory T cells and on dendritic cells

(2016) Giovanni Stallone et al.   Journal of Translational Medicine

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

(2016) Frank B. Cortazar et al.   KIDNEY INTERNATIONAL

Ipilimumab-associated minimal-change disease

(2016) Jason M. Kidd et al.   KIDNEY INTERNATIONAL

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Discovery of urinary metabolomic biomarkers for early detection of acute kidney injury

(2016) A Jin Won et al.   Molecular BioSystems

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

(2016) Jie Shen et al.   PLoS One

Pathological  -synuclein transmission initiated by binding lymphocyte-activation gene 3

(2016) X. Mao et al.   SCIENCE

Mixed acute kidney allograft rejection after an antiprogrammed cell death protein 1 antibody treatment for lung epidermoid carcinoma

(2016) Mathilde Tamain et al.   TRANSPLANT INTERNATIONAL

Re-examining the Nature and Function of Self-Reactive T cells

(2016) David M. Richards et al.   TRENDS IN IMMUNOLOGY

Nivolumab-associated acute glomerulonephritis: a case report and literature review

(2016) Kyungsuk Jung et al.   BMC Nephrology

The Obesity Paradox in Cancer: a Review

(2016) Hannah Lennon et al.   Current Oncology Reports

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

(2016) Krista Dubin et al.   Nature Communications

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer

(2016) Ruea-Yea Huang et al.   OncoImmunology

Antitumor activity of nivolumab on hemodialysis after renal allograft rejection

(2016) Michael Ong et al.   Journal for ImmunoTherapy of Cancer

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports

(2016) Noha Abdel-Wahab et al.   PLoS One

Complement Modulation of Anti-Aging Factor Klotho in Ischemia/Reperfusion Injury and Delayed Graft Function

(2015) G. Castellano et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

Oscillatory mTOR inhibition and Tregincrease in kidney transplantation

(2015) M. Sabbatini et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Cancer immunotherapy: harnessing the immune system to battle cancer

(2015) Yiping Yang   JOURNAL OF CLINICAL INVESTIGATION

Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery

(2015) W. R. Zhang et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion

(2015) V. Andrade-Oliveira et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Soluble Serum αKlotho Is a Potential Predictive Marker of Disease Progression in Clear Cell Renal Cell Carcinoma

(2015) Margherita Gigante et al.   MEDICINE

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

(2015) T. Kouo et al.   Cancer Immunology Research

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

(2015) Ahmad A. Tarhini et al.   Journal for ImmunoTherapy of Cancer

A Systematic Review of Conversion From Calcineurin Inhibitor to Mammalian Target of Rapamycin Inhibitors for Maintenance Immunosuppression in Kidney Transplant Recipients

(2014) W. H. Lim et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

(2014) Sander Kelderman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Kidney injuries related to ipilimumab

(2014) Hassane Izzedine et al.   INVESTIGATIONAL NEW DRUGS

Both PD-1 Ligands Protect the Kidney from Ischemia Reperfusion Injury

(2014) Katarzyna Jaworska et al.   JOURNAL OF IMMUNOLOGY

A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use

(2014) Mei-Ling Blank et al.   KIDNEY INTERNATIONAL

Intestinal Microbiota-Kidney Cross Talk in Acute Kidney Injury and Chronic Kidney Disease

(2014) Sanjeev Noel et al.   NEPHRON CLINICAL PRACTICE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Co-Inhibitory Pathways and Their Importance in Immune Regulation

(2014) Naoka Murakami et al.   TRANSPLANTATION

Erratum to: Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population

(2014) Alberto Breda et al.   WORLD JOURNAL OF UROLOGY

Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data

(2014) G. A. Knoll et al.   BMJ-British Medical Journal

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

(2013) J. Delyon et al.   ANNALS OF ONCOLOGY

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

(2013) Andrew M. Intlekofer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

T-helper-1-cell cytokines drive cancer into senescence

(2013) Heidi Braumüller et al.   NATURE

Understanding immunosenescence to improve responses to vaccines

(2013) Jörg J Goronzy et al.   NATURE IMMUNOLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Autocrine Adenosine Signaling Promotes Regulatory T Cell-Mediated Renal Protection

(2012) G. R. Kinsey et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation

(2012) Sylvie Euvrard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury: a prospective study

(2012) Longxiang Su et al.   BMC Nephrology

Hallmarks of human “immunosenescence”: adaptation or dysregulation?

(2012) Graham Pawelec   Immunity & Ageing

Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients

(2011) Eric A. Engels et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Shifting the balance: antibiotic effects on host–microbiota mutualism

(2011) Benjamin P. Willing et al.   NATURE REVIEWS MICROBIOLOGY

Role of Indoxyl Sulfate in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Experimental and Clinical Effects of Oral Sorbent AST-120

(2011) Toshimitsu Niwa   THERAPEUTIC APHERESIS AND DIALYSIS

Sirolimus and Proteinuria in Renal Transplant Patients: Evidence for a Dose-Dependent Effect on Slit Diaphragm-Associated Proteins

(2011) Giovanni Stallone et al.   TRANSPLANTATION

An Oscillatory Switch in mTOR Kinase Activity Sets Regulatory T Cell Responsiveness

(2010) Claudio Procaccini et al.   IMMUNITY

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

T helper 1, 2 and 17 cell subsets in renal transplant patients with delayed graft function

(2010) Antonia Loverre et al.   TRANSPLANT INTERNATIONAL

LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)

(2009) Sanjiv S. Agarwala et al.   EUROPEAN JOURNAL OF CANCER

Interleukin-23/Th17 pathways and inflammatory bowel disease

(2009) Clara Abraham et al.   INFLAMMATORY BOWEL DISEASES

Interferon-alpha (IFN-α)–conditioned DC Preferentially Stimulate Type-1 and Limit Treg-type In Vitro T-cell Responses From RCC Patients

(2009) Margherita Gigante et al.   JOURNAL OF IMMUNOTHERAPY

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

(2009) Erika von Euw et al.   Journal of Translational Medicine

Anti-CTLA4 Antibody–Induced Lupus Nephritis

(2009) Fouad Fadel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dysfunctional DC subsets in RCC patients: Ex vivo correction to yield an effective anti-cancer vaccine

(2008) M. Gigante et al.   MOLECULAR IMMUNOLOGY

AST-120 Treatment in Pre-Dialysis Period Affects the Prognosis in Patients on Hemodialysis

(2008) Haruhiko Ueda et al.   RENAL FAILURE

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE